Advertisement

Effects of immunotherapeutic strategies on cerebrospinal fluid parameters in multiple sclerosis

  • K. J. B. Lamers
  • S. T. F. M. Frequin
  • O. R. Hommes

Abstract

Therapeutic strategies in MS are generally based on treatment with anti-inflammatory, immunosuppressive or immunomodulatory agents. Most applied therapeutic agents in MS are: corticosteroids, cyclophosphamide, azathioprine, cyclosporine, interferon, total lymphoid irradiation, plasma exchange, monoclonal antibodies, copolymer-I and immunoglobulins. Modes of administration are: oral, intramuscular, intravenous or intrathecal; administration of drugs can be carried out by both a short course of high dose or a chronic low dose during an extended period.

Keywords

Multiple Sclerosis Multiple Sclerosis Patient Immunotherapeutic Strategy Myelin Basic Protein Level Chronic Progressive 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frequin STFM, Barkhof F, Lamers KJB, Hommes OR, Borm GF (1992) CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. Acta Neurol Scand 86:291–297PubMedCrossRefGoogle Scholar
  2. 2.
    Frequin STFM, Lamers KJB, Barkhof F, Brom GF, Hommes OR (1994) Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. Acta Neurol Scand 90:105–110PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson TJ, MacG Donaldson I, Sheat M, George PM (1990) Methylprednisolone in multiple sclerosis exacerbation: changes in CSF parameters. Aus NZ J Med 20:794–797CrossRefGoogle Scholar
  4. 4.
    Wender M, Tokarz E, Michalowska G, Wajgt A (1986) Therapeutic trials of multiple sclerosis and intrathecal IgG production. Ital J Neurol Sci 7:205–208PubMedCrossRefGoogle Scholar
  5. 5.
    Durelli L, Cocito D, Riccio A, Barile C, Bergamasco B, Baggio GF, Perla F, Delsedime M, Gusmaroli G, Berganini L (1986) High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurol 36:238–243Google Scholar
  6. 6.
    Warren KG, Catz I, Jeffrey VM, Carroll DJ (1986) Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Can J Neurol Sci 13:25–30PubMedGoogle Scholar
  7. 7.
    Caputo D, Zaffaroni M, Ghezzi A, Cazzullo CL (1987) Azathioprine reduces intrathecal IgG synthesis in multiple sclerosis. Acta Neurol Scand 75:84–86PubMedCrossRefGoogle Scholar
  8. 8.
    Staugaitis SM, Shapshak P, Myers LW, Ellison GW, Tourtellotte WW, Lee M (1985) Azathioprine and steroids are not more effective in decreasing multiple sclerosis intra-blood-brain-barrier IgG synthesis than steroids alone. Ann Neurol 18:356–357PubMedCrossRefGoogle Scholar
  9. 9.
    Hommes OR, Lamers KJB, Geel van WJA (1985) Intrathecal IgG synthesis and IgG index after intensive and chronic immunosuppressive treatment of multiple sclerosis. Ann N Y Acad Sci 436:410–417CrossRefGoogle Scholar
  10. 10.
    Wajgt A, Górny M, Szcechowski L, Grzybowski G, Ochudlo S (1989) Effect of immunosuppressive therapy on humoral immune response in multiple sclerosis. Acta Med Pol 30(3–4):121–128PubMedGoogle Scholar
  11. 11.
    Panitch HS, Francis GS, Hooper CJ, Merigan TC, Johnson KP (1985) Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon. Ann Neurol 18:434–438PubMedCrossRefGoogle Scholar
  12. 12.
    Baumhefner RW, Tourtellotte WW, Syndulko K, Staugaitis A, Shapshak P (1989) Multiple sclerosis intra-blood-brain-barrier IgG synthesis: effect of pulse intravenous and intrathecal corticosteroids. Ital J Neurol Sci 10:19–32PubMedCrossRefGoogle Scholar
  13. 13.
    Confavreux C, Chapuis-Cellier C, Arnaud P, Robert O, Aimard G, Devic M (1986) Oligoclonal “fingerprint” of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. J Neurol Neurosurg Psych 49:1308–1312CrossRefGoogle Scholar
  14. 14.
    Munster van ETL (1991) Thesis, pp 53–71Google Scholar
  15. 15.
    Sharief MK, Thompson EJ (1991) Intrathecal immunoglobulin M synthesis in multiple sclerosis. Brain 114:181–195PubMedGoogle Scholar
  16. 16.
    Durelli L, Poccardi G, Cavallo R (1991) CD8+ high CD11b+ low T cells (T suppressor-effectors) in multiple sclerosis cerebrospinal fluid are increased during high dose corticosteroid treatment. J Neuroimmunol 31:221–228PubMedCrossRefGoogle Scholar
  17. 17.
    Huber M, Bamborschke S, Assheuer J, Heiß WD (1988) Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. J Neurol 235:171–173PubMedCrossRefGoogle Scholar
  18. 18.
    Uitdehaag BMJ, Nillesen WM, Hommes OR (1989) Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid. Acta Neurol Scand 79:12–17PubMedCrossRefGoogle Scholar
  19. 19.
    Salmaggi A, Milanese C, Eoli M, Mantia la L, Nespolo A, Dufour A (1994) Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients. Int J Neurosci 76:305–312PubMedCrossRefGoogle Scholar
  20. 20.
    Dufour A, Salmaggi A, Mantia la L, Eoli M, Nespolo A, Milanese C (1994) High-dose methylprednisolone treatment-induced changes in immunological parameters in progressive MS patients. Int J Neurosci 75:119–128PubMedCrossRefGoogle Scholar
  21. 21.
    Frequin STFM, Lamers KJB, Barkhof F, Jongen PJH, Hommer OR (1993) T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Acta Neurol Scand 88:80–86PubMedCrossRefGoogle Scholar
  22. 22.
    Brinkman CJJ, Nillesen WM, Hommes OR (1984) The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis. Acta Neurol Scand 69:90–96PubMedCrossRefGoogle Scholar
  23. 23.
    Polman CH, Groot de CJA, Koetsier JC, Sminia T, Veerman AJP (1987) Cerebrospinal fluid cells in multiple sclerosis and other neurological diseases: an immunocytochemical study. J Neurol 234:19–22PubMedCrossRefGoogle Scholar
  24. 24.
    Barkhof F, Frequin STFM, Hommes OR, Lamers KJB, Scheltens P, Geel van WJA, Valk J (1992) A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurol 42:63–67Google Scholar
  25. 25.
    Lamers KJB, Uitdehaag BMJ, Hommes OR, Doesburg W, Wevers RA, Geel van WJA (1988) The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg Psych 51:1334–1337CrossRefGoogle Scholar
  26. 26.
    Whitaker JN, Layton BA, Herman PK, Kachelhofer RD, Burgard S, Bartolucci AA (1993) Correlation of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients with their response to glucocorticoid treatment. Ann Neurol 33:10–17PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1996

Authors and Affiliations

  • K. J. B. Lamers
    • 1
  • S. T. F. M. Frequin
    • 2
  • O. R. Hommes
    • 1
  1. 1.Institute of NeurologyUniversity Hospital NijmegenNijmegenThe Netherlands
  2. 2.St. Antonius HospitalInstitute of NeurologyNieuwegeinThe Netherlands

Personalised recommendations